Seasonal Influenza Vaccines Market Strategic Assessment 2019: Sanofi S.A., CSL Limited, GlaxoSmithKline Plc., and Medimmune
The Advisory Committee on Immunization Practices (ACIP) 2017-2018 recommendations mention routine annual influenza vaccination for everyone aged 6 months and above with either inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). The major reasons behind influenza are broad host specificity and high variability of viruses. Moreover, virus neutralizing antibodies induced by various vaccines are strain specific, which leads to vaccinations being updated each year. To tackle this issue, various government and private research organizations are engaged in developing novel...
View full press release